CPXM2 Inhibitors

Chemical inhibitors of CPXM2 operate primarily through the sequestration of metal ions that are essential for the protein's enzymatic activity. CPXM2, as a carboxypeptidase, requires a zinc ion at its active site to catalyze the cleavage of amino acids from the carboxy terminus of proteins. Chelating agents such as EDTA and 1,10-Phenanthroline are adept at binding metal ions, thereby depleting zinc availability for CPXM2, leading to an inhibition of its activity. D-Penicillamine, with its metal chelating properties, functions in a similar fashion by binding to the zinc ion, which is indispensable for CPXM2's catalytic function. Phosphoramidon and Marimastat, both known metalloprotease inhibitors, can bind to the zinc ion within the active site of CPXM2, resulting in a block of its enzymatic activity. Similarly, Batimastat and Ilomastat may also inhibit CPXM2 by chelating the active site zinc ion, thus preventing the enzymatic processing of substrates by CPXM2.

Other inhibitors, such as Captopril, albeit primarily known for inhibiting angiotensin-converting enzyme (ACE), can engage with CPXM2 through its zinc-binding sulfhydryl group. This interaction effectively inhibits CPXM2 by interfering with the zinc ion at its active site. TAPI-0 and TAPI-1, inhibitors of the ADAM family of metalloproteases, are capable of inhibiting CPXM2 by a similar zinc chelation mechanism. NNGH, a hydroxamate-based inhibitor, targets metalloproteases and can inhibit the enzymatic activity of CPXM2 by coordinating with the zinc ion in the active site.